ADC Therapeutics (ADCT) Share-based Compensation (2020 - 2026)

ADC Therapeutics (ADCT) has reported Share-based Compensation for 7 consecutive years, with $2.4 million the latest figure, recorded in Q1 2026.

• Quarterly Share-based Compensation rose 0.87% year-over-year to $2.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.9 million (down 21.57% YoY) and the FY2025 annual result came in at $6.9 million, up 5.13% from the prior year.
• Share-based Compensation climbed to $2.4 million in Q1 2026 per ADCT's latest filing, from $673000.0 in the prior quarter.
• Over the last five years, Share-based Compensation for ADCT reached as high as $14.6 million in Q3 2022 and fell as low as $158000.0 in Q1 2024.
• A 5-year average of $4.6 million and a median of $2.2 million in 2023 frame the typical range for Share-based Compensation.
• Annual changes were most pronounced in 2024 — Share-based Compensation plunged 98.04% — and 2025, when it jumped 1432.28%.
• Year by year, Share-based Compensation stood at $7.5 million in 2022, then sank by 70.56% to $2.2 million in 2023, then decreased by 27.21% to $1.6 million in 2024, then plunged by 58.35% to $673000.0 in 2025, then soared by 262.85% to $2.4 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $2.4 million, $673000.0, and $2.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.